Table 1.
Characteristics of 2125 patients by age group.
| Age at diagnosis (years) | |||||
|---|---|---|---|---|---|
| ≤40 | 41–50 | 51–60 | >60 | P* | |
| N(%) | N(%) | N(%) | N(%) | ||
| Tumor sizes | 0.7257 | ||||
| ≤2 cm | 218 (40.2) | 320 (42.2) | 219 (39.5) | 114 (42.4) | |
| >2 cm | 324 (59.8) | 439 (57.8) | 336 (60.5) | 155 (57.6) | |
| Node statue | 0.0134 | ||||
| N0 | 265 (48.9) | 423 (55.7) | 287 (51.7) | 160 (59.5) | |
| N+ | 277 (51.0) | 336 (44.3) | 268 (48.3) | 109 (40.5) | |
| Stage | 0.0126 | ||||
| I+II | 394 (72.7) | 590 (77.7) | 418 (75.3) | 222 (82.5) | |
| III | 148 (27.3) | 169 (22.3) | 137 (24.7) | 47 (17.5) | |
| Histologic Grade | 0.3285 | ||||
| Low/moderate | 378 (69.7) | 529 (69.7) | 397 (71.5) | 192 (71.4) | |
| High | 146 (27.0) | 171 (22.5) | 119 (21.4) | 65 (24.2) | |
| unknown | 18 (3.3) | 59 (7.8) | 39 (7.0) | 12 (4.4) | |
| ER status | 0.0026 | ||||
| positive | 384 (70.9) | 526 (69.3) | 339 (61.1) | 180 (66.9) | |
| negative | 158 (29.1) | 233 (30.7) | 216 (38.9) | 89 (33.1) | |
| PR status | <0.0001 | ||||
| positive | 377 (69.6) | 489 (64.4) | 282 (50.8) | 157 (58.4) | |
| negative | 165 (30.4) | 270 (35.6) | 273 (49.2) | 112 (41.6) | |
| HER2 status | 0.0015 | ||||
| positive | 162 (29.9) | 229 (30.2) | 199 (35.9) | 61 (22.7) | |
| negative | 380 (70.1) | 530 (69.8) | 356 (64.1) | 208 (77.3) | |
| Ki67 | 0.0065 | ||||
| Low | 168 (31.0) | 283 (37.3) | 201 (36.2) | 124 (46.1) | |
| High | 231 (42.6) | 280 (36.9) | 225 (40.5) | 98 (36.4) | |
| unknown | 143 (26.4) | 196 (25.8) | 129 (23.3) | 47 (17.5) | |
| Molecular subtype | <0.0001 | ||||
| Luminal A | 112 (20.7) | 183 (24.1) | 100 (18.0) | 71 (26.4) | |
| Luminal B Her-2 (+) | 92 (17.0) | 114 (15.0) | 72 (13.0) | 24 (8.9) | |
| Luminal B Her-2 (−) | 186 (34.3) | 232 (30.6) | 168 (30.3) | 86 (32.0) | |
| HER-2 over- expression | 70 (12.9) | 114 (15.0) | 127 (22.9) | 36 (13.4) | |
| Triple negative | 82 (15.1) | 116 (15.3) | 88 (15.8) | 52 (19.3) | |
| Chemotherapy | <0.0001 | ||||
| Yes | 526 (97.1) | 741 (97.6) | 539 (97.1) | 182 (67.7) | |
| No | 16 (2.9) | 18 (2.4) | 16 (2.9) | 87 (32.3) | |
| Endocrine-therapy | <0.0001 | ||||
| Yes | 354 (65.3) | 477 (62.9) | 294 (53.0) | 143 (53.2) | |
| No | 188 (34.7) | 282 (37.1) | 261 (47.0) | 126 (46.8) | |
| Trastuzumab | 0.2328 | ||||
| Yes | 16 (2.9) | 18 (2.4) | 11 (2.0) | 2 (0.7) | |
| No | 526 (97.1) | 741 (97.6) | 544 (98.0) | 267 (99.3) | |
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
*P value from χ2 test.